SCHEMBL8737314

SCHEMBL8737314

Cc1cc(F)c(Oc2ccccc2)c(Cl)c1

nearest known ligand 0.40

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
NPBWR1 P48145 1/20 0.40
MCHR1 Q99705 1/20 0.40
MAPT P10636 3/20 0.39
HPGD P15428 1/20 0.39
MAPK1 P28482 1/20 0.39
L3MBTL1 Q9Y468 1/20 0.39
RHEB Q15382 3/20 0.37
LTA4H P09960 2/20 0.37
TSHR P16473 1/20 0.37
KMT2A Q03164 2/20 0.36
MEN1 O00255 1/20 0.36
POLB P06746 1/20 0.36
TDP1 Q9NUW8 1/20 0.36
CA12 O43570 1/20 0.36
CA1 P00915 1/20 0.36
CA2 P00918 1/20 0.36
CA7 P43166 1/20 0.36
CA13 Q8N1Q1 1/20 0.36
STK39 Q9UEW8 1/20 0.35
LPAR1 Q92633 1/20 0.34

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL13556591 0.87 NPBWR1 (0.44) NPBWR1MCHR1MAPTHPGDMAPK1
SCHEMBL778762 0.87 LTA4H (0.44) MAPTHPGDMAPK1L3MBTL1LTA4H
SCHEMBL11660811 0.82 STK39 (0.46) MAPTL3MBTL1RHEBLTA4HTSHR
SCHEMBL14021948 0.82 LMNA (0.46) MAPTHPGDTDP1HTTSMN1; SMN2
SCHEMBL778774 0.81 MAOB (0.44) MAPTL3MBTL1LTA4HTSHRKMT2A
SCHEMBL778776 0.77 PTGDR2 (0.42) MAPTHPGDKMT2AMEN1POLB
SCHEMBL25000023 0.74 SLC6A4 (0.44) NPBWR1MCHR1MAPTHPGDKMT2A
SCHEMBL12216295 0.74 ACHE (0.43) MAPTHPGDMAPK1L3MBTL1KMT2A
SCHEMBL328393 0.73 MAPT (0.41) NPBWR1MAPTKMT2AMEN1POLB
SCHEMBL1129268 0.72 ALDH1A1 (0.44) NPBWR1MCHR1MAPTRHEBLTA4H

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20120129893-A1 Inhibition Of Raf Kinase Using Substituted Heterocyclic Ureas DUMAS JACQUES (US) 2012-05-24 US disclosed
US-20120129893-A1 Inhibition Of Raf Kinase Using Substituted Heterocyclic Ureas DUMAS JACQUES (US) 2012-05-24 US disclosed
US-20070244120-A1 INHIBITION OF RAF KINASE USING SUBSTITUTED HETEROCYCLIC UREAS BAYER HEALTHCARE LLC 2007-10-18 US disclosed
US-20070244120-A1 INHIBITION OF RAF KINASE USING SUBSTITUTED HETEROCYCLIC UREAS BAYER HEALTHCARE LLC 2007-10-18 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20070244120-A1 INHIBITION OF RAF KINASE USING SUBSTITUTED HETEROCYCLIC UREAS BRAF, RAF1, ARAF NPBWR1 4366/4885MCHR1 4211/4885MAPT 3056/4885
US-20120129893-A1 Inhibition Of Raf Kinase Using Substituted Heterocyclic Ureas BRAF, RAF1, ARAF NPBWR1 4366/4885MCHR1 4211/4885MAPT 3056/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.